Go All-In On Actavi...
Health Care: Drugs
Aastrom Biosciences Inc. (ASTM: NASDAQ)
$0.51 0.00 | -0.29%
06/18/13 - 03:59 PM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Jun 2010 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -29.47M | -19.67M | -19.09M | -17.73M |
| Operating Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | -19.00K | 16.00K | -9.00K | 42.00K |
| (Increase) Decrease in Inventories | 0.00 | 0.00 | 0.00 | 1.00K |
| (Increase) Decrease In Other Current Assets | 312.00K | -210.00K | -43.00K | 72.00K |
| (Decrease) Increase In Payables | -375.00K | 63.00K | 976.00K | 896.00K |
| (Decrease) Increase In Other Current Liabilities | 0.00 | 246.00K | 110.00K | 331.00K |
| (Increase) Decrease In Other Working Capital | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Cash Items | -638.00K | -5.59M | 8.54M | 710.00K |
| Net Cash From Continuing Operations | -29.54M | -24.49M | -9.25M | -15.08M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -29.54M | -24.49M | -9.25M | -15.08M |
| Sale of Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 0.00 | 0.00 | 5.00M | 0.00 |
| Purchases of Property, Plant & Equipment | -273.00K | -1.03M | -305.00K | -120.00K |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Short-Term Investments | 0.00 | 0.00 | 0.00 | -5.00M |
| Other Cash from Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -273.00K | -1.03M | 4.70M | -5.12M |
| Issuance of Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 346.00K | 32.00K | 21.80M | 17.53M |
| Repayment of Long-Term Debt | -40.00K | -227.00K | -119.00K | -479.00K |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | 37.62M | 0.00 | 0.00 | 277.00K |
| Net Cash From Financing Activities | 37.93M | -195.00K | 21.69M | 17.32M |
| Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | 8.11M | -25.72M | 17.13M | -2.88M |
Portfolios with ASTM
- Portfolio NameUser Type
- ContributorStocks Under-$10 Setting Up...
- UserMark
- UserMy Portfolio As of 7/15/2012
- Userdonnieny7 Portfolio 1 Specu...
- ContributorBreakout Stocks Of The Week...
- Contributor10 Cheap Biotech Stocks Tha...
- Usermrtimrx WatchList
- UserMy Folly
- Userbosw119
- Usergellis1360 Portfolio 1
Latest ASTM Headlines from TheStreet
- Aastrom Biosciences Reports First Quarter 2013 Financial Results 05.08.13 | 04:05 pm
- Aastrom To Host First Quarter 2013 Investor Call On May 8, 2013 05.03.13 | 04:05 pm
- Aastrom To Hold Annual Meeting Of Shareholders On May 2, 2013 04.25.13 | 04:04 pm
- Aastrom Biosciences Announces First Patients Treated In IxCELL-DCM Clinical Study Of Ixmyelocel-T 04.19.13 | 09:04 am
- Aastrom Biosciences To Present At Multiple Conferences In April 04.09.13 | 04:04 pm
- Aastrom Biosciences Announces First Patients Enrolled In IxCELL-DCM Phase 2b Clinical Trial Of Ixmyelocel-T 04.04.13 | 09:04 am
- Aastrom Biosciences Announces Strategic Change In Research And Development Programs To Focus On Dilated Cardiomyopathy And Other Rare Disease Indications 03.27.13 | 08:03 am
- Aastrom Biosciences Reports Fourth-Quarter And Year-End 2012 Financial Results 03.18.13 | 04:03 pm
- Aastrom To Host Fourth Quarter 2012 Investor Call On March 18, 2013 03.12.13 | 04:03 pm
- Aastrom Board Of Directors Names Dominick C. Colangelo President And Chief Executive Officer 03.06.13 | 04:03 pm
Press Releases for ASTM
Partner Headlines for ASTM
- Is Takeda Interested In Aastrom Bio? - Seeking Alpha 02.27.13 | 09:02 am
- Seven Innovative Biotechs That Could Soar by Year-End: George Zavoico - NASDAQ 09.13.12 | 05:09 pm
- Cell Therapy Outlook Starting To Match Clinical Results - Seeking Alpha 08.21.12 | 09:08 am
- Talisman Energy UPGRADED to Buy and 2 Analyst-Upgraded Shares to Notice - Wall St. Cheat Sheet 07.24.12 | 06:07 am
- Analysts Release These New Equity Ratings Monday - Wall St. Cheat Sheet 06.04.12 | 03:06 am
- Follow the Analyst Leader: New Stock Coverage to Watch - Wall St. Cheat Sheet 05.31.12 | 04:05 am
- Medgenics Moving In Record Time - Seeking Alpha 05.21.12 | 09:05 am
- Aastrom Biosciences Announces Initiation of Patient Enrollment in REVIVE Phase 3 Clinical Trial of Ixmyelocel-T - Benzinga 02.29.12 | 04:02 pm
- 10 Biotech Stocks Undervalued By Levered Free Cash Flows - Seeking Alpha 12.07.11 | 08:12 am
- Aastrom Bio: Final RESTORE Data Looks Solid - Seeking Alpha 11.15.11 | 09:11 am
